However, since the publication of this SR, the therapeutic landscape for HF and hypertension has evolved significantly with the introduction of novel therapeutic agents, such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRA), and angiotensin receptor-neprilysin inhibitors (ARNI). Here, SLC5A2 is linked to Hypertension.